A Single Centre, 2-period, Randomized, Open-label Phase 1 Study to Assess the Relative Bioavailability of a Mesylate Salt Capsule of GSK3640254 Compared to a Hydrochloride Salt Capsule in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs GSK 3640254 (Primary)
- Indications HIV infections
- Focus First in man; Pharmacokinetics
- Sponsors ViiV Healthcare
- 11 Oct 2018 Status changed from recruiting to completed.
- 23 Jul 2018 Planned End Date changed from 14 Jul 2018 to 2 Aug 2018.
- 23 Jul 2018 Planned primary completion date changed from 14 Jul 2018 to 2 Aug 2018.